Company news: BMS goes over the patent cliff

Share this article:
Sales of Bristol-Myers Squibb's Plavix plunged 96% in the third quarter over the same period last year, contributing mightily to an overall 30% drop in sales of the company's products for the quarter, to $3.7 billion. BMS's patent cliff woes include Avapro and Avalide as well, and the company saw its HCV candidate, BMS-986094, fail. CEO Lamberto Andreotti put a brave face on it, conceding a "challenging" quarter but touting the finalization of the company's Amylin acquisition and saying: “We remain strong and well-positioned for future success as demonstrated by the achievement of regulatory milestones for Eliquis and Orencia, the presentation of long-term survival data for Yervoy, the completion of our acquisition of Amylin, and the performance of our key brands.”
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.